TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates

Company Performance - TELA Bio, Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -11.76% [1] - The company posted revenues of $20.69 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 5.53%, but showing an increase from $18.96 million in the same quarter last year [2] - TELA Bio has not surpassed consensus EPS estimates over the last four quarters and has topped consensus revenue estimates only once during that period [2] Stock Performance - TELA Bio shares have declined approximately 62.3% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for TELA Bio is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $24.8 million, and for the current fiscal year, it is -$0.79 on revenues of $85.4 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where TELA Bio operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]